[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021005010A - Metodos y composiciones para prevenir y tratar la aterosclerosis y enfermedades relacionadas. - Google Patents

Metodos y composiciones para prevenir y tratar la aterosclerosis y enfermedades relacionadas.

Info

Publication number
MX2021005010A
MX2021005010A MX2021005010A MX2021005010A MX2021005010A MX 2021005010 A MX2021005010 A MX 2021005010A MX 2021005010 A MX2021005010 A MX 2021005010A MX 2021005010 A MX2021005010 A MX 2021005010A MX 2021005010 A MX2021005010 A MX 2021005010A
Authority
MX
Mexico
Prior art keywords
sdss1
fragments
variants
proteins
individual
Prior art date
Application number
MX2021005010A
Other languages
English (en)
Inventor
Yinghao Zhang
Jingpeng Fu
Yao Wang
Guirui Yan
Original Assignee
Shanghai Clear Fluid Biomedical Science & Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Clear Fluid Biomedical Science & Tech Co Ltd filed Critical Shanghai Clear Fluid Biomedical Science & Tech Co Ltd
Publication of MX2021005010A publication Critical patent/MX2021005010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)

Abstract

Un método para prevenir o tratar la aterosclerosis o enfermedades relacionadas con la aterosclerosis en un individuo que lo necesite, que comprende administrar al individuo una cantidad terapéuticamente efectiva de proteína sDSS1 o un fragmento o variante de la misma, un ácido nucleico que codifica la proteína sDSS1 o un fragmento o variante de la misma o un vector que contiene el ácido nucleico, trasplantar en el individuo con una célula que expresa la proteína sDSS1 o un fragmento o variante de la misma, o tejidos u órganos que contienen la proteína sDSS1 o un fragmento o variante de la misma o el ácido nucleico, y/o infundir en el individuo suero o fluido intersticial que contiene la proteína sDSS1 o un fragmento o variante de la misma o el ácido nucleico.
MX2021005010A 2018-09-10 2019-09-10 Metodos y composiciones para prevenir y tratar la aterosclerosis y enfermedades relacionadas. MX2021005010A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811052915.1A CN110882378A (zh) 2018-09-10 2018-09-10 一种蛋白在制备预防和治疗动脉粥样硬化及并发症药物的应用
PCT/CN2019/105220 WO2020052570A1 (zh) 2018-09-10 2019-09-10 预防和治疗动脉粥样硬化及相关疾病的方法和组合物

Publications (1)

Publication Number Publication Date
MX2021005010A true MX2021005010A (es) 2022-11-30

Family

ID=69745256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005010A MX2021005010A (es) 2018-09-10 2019-09-10 Metodos y composiciones para prevenir y tratar la aterosclerosis y enfermedades relacionadas.

Country Status (11)

Country Link
US (1) US20220040257A1 (es)
EP (1) EP3854804A4 (es)
JP (1) JP7573531B2 (es)
KR (1) KR20210075087A (es)
CN (2) CN110882378A (es)
AU (1) AU2019339037A1 (es)
CA (1) CA3112416A1 (es)
IL (1) IL281394A (es)
MX (1) MX2021005010A (es)
SG (1) SG11202102442WA (es)
WO (1) WO2020052570A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114480382A (zh) * 2020-11-12 2022-05-13 北京大学 用于抑制SURF4基因表达的RNAi试剂和组合物
CN115287276A (zh) * 2022-03-07 2022-11-04 兰州大学 Sem1蛋白、表达sem1蛋白工程化益生菌在制备治疗和/或预防心脏病药物中的应用
WO2024056028A1 (en) * 2022-09-15 2024-03-21 Shanghai Puyou Biochemical Co., Ltd. Analgesic polypeptide
WO2024188256A1 (en) * 2023-03-14 2024-09-19 Shanghai Puyou Biochemical Co., Ltd. Use of a polypeptide for the prevention or treatment of allergic conjunctivitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5781144A (en) * 1996-07-03 1998-07-14 Litton Applied Technology Wide band video signal denoiser and method for denoising
CA2399548A1 (en) * 2002-08-23 2004-02-23 Andre Tremblay Growth hormone-releasing peptides as negative modulators of atherosclerosis and hypercholesterolemia
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
CN100364563C (zh) * 2004-12-10 2008-01-30 广州中医药大学 抑制丝裂原活化蛋白激酶p38亚族的组合物及其应用
US20090311271A1 (en) * 2008-05-29 2009-12-17 Wyeth Methods and Compositions for Selective Inhibition of Ligand Binding to the Lectin-Like Receptor for Oxidized Low Density Lipoprotein (LOX-1)
CN101654481A (zh) * 2009-07-02 2010-02-24 中国人民解放军第四军医大学 一种抑制动脉粥样硬化的天然抗氧化低密度脂蛋白抗体
CN102863525B (zh) * 2011-07-04 2014-06-04 武汉大学 一种重组人apoE拟肽及制备方法和应用
CN103215292B (zh) * 2012-01-18 2015-10-07 中国科学院生物物理研究所 人Pcid2蛋白的可溶性表达及抗人Pcid2蛋白的单克隆抗体2D7-F11和分泌该抗体的杂交瘤细胞系
CN113150105B (zh) * 2016-07-04 2024-02-20 上海普佑生物医药有限公司 一种新型天然蛋白及其应用
CN110302362B (zh) * 2018-03-20 2024-04-05 上海普佑生物医药有限公司 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用

Also Published As

Publication number Publication date
JP7573531B2 (ja) 2024-10-25
KR20210075087A (ko) 2021-06-22
AU2019339037A1 (en) 2021-05-13
WO2020052570A1 (zh) 2020-03-19
CN112839953B (zh) 2024-06-11
CN110882378A (zh) 2020-03-17
EP3854804A1 (en) 2021-07-28
JP2022500491A (ja) 2022-01-04
US20220040257A1 (en) 2022-02-10
IL281394A (en) 2021-04-29
CN112839953A (zh) 2021-05-25
SG11202102442WA (en) 2021-04-29
CA3112416A1 (en) 2020-03-19
EP3854804A4 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
MX2021005010A (es) Metodos y composiciones para prevenir y tratar la aterosclerosis y enfermedades relacionadas.
AR120138A1 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2019005125A (es) Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
BR112014026088A2 (pt) produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos
BR112019010250A2 (pt) novas proteínas klotho recombinantes e composições e métodos que envolvem as mesmas
IN2014CN04645A (es)
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
PH12019502522A1 (en) Oncolytic virus and method
MX2020006944A (es) Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer.
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
Larcher et al. Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa
BR112023020490A2 (pt) Composições e métodos para expressão de transgenes oculares
WO2006004675A3 (en) Production of tissue factor in plants
SE0000597D0 (sv) Novel antibody
ZA202110356B (en) Stabilized mutants of quorum quenching lactonase and use thereof in treatment of pathogens